Month: August 2020

WAYNE, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2020 and provided research and development (R&D) and business highlights.“As the pandemic evolves, our team has continued to work hard to make the appropriate business adjustments, advance our pipeline and execute through these uncertain times,” said Dr. Neal Walker, President and CEO of Aclaris. “In the second quarter, we dosed the first subject in our Phase 2a trial of ATI-450 as a potential treatment for moderate to severe rheumatoid arthritis. We are also proud to be participating in the effort to find effective therapeutics for COVID-19 by supporting...

GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. With this milestone, the data readout for the Day 28 immunogenicity endpoint remains on target for Q4 2020.The clinical trial has enrolled 42 evaluable healthy subjects to receive intranasally administered NasoShield or placebo and be followed for 6 months following dosing. The primary immunogenicity readouts are the serum antibody response to protective antigen and toxin-neutralizing antibody titer 28 and 56 days after dosing. As with Altimmune’s other vaccine programs, stimulation of a mucosal IgA immune response in the nasal cavity will also be assessed as...

Seoul, Aug. 07, 2020 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games based in South Korea, today announced its unaudited financial results for the second quarter ended June 30, 2020, prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board and business updates.SECOND QUARTER 2020 HIGHLIGHTSTotal revenues were KRW 88,458 million (US$ 73,684 thousand), representing a 20.7% increase from the first quarter ended March 31, 2020 (“QoQ”) and a 13.2% increase from the second quarter ended June 30, 2019 (“YoY”).Operating profit was KRW 16,313 million (US$ 13,588 thousand), representing a 57.5% increase QoQ and a 25.5% increase YoY.Profit before income tax expenses was KRW 16,335million...

AS Tallinna Sadam invites all the stakeholders to join its investor conference webinar, introducing the results for Q2 and 6 months of 2020. The webinar is scheduled for 14 August 2020 at 11.00 am EET and will be held in English.The Chairman of the Management Board Valdo Kalm and Chief Financial Officer Marko Raid will be presenting the results and answering the questions. The questions will be answered after the presentation. Due to limited webinar time, we encourage participants to send their questions beforehand to e-mail: m.zirel@ts.ee .Participating in the webinar:To join the webinar, please click hereWhen joining the webinar for the first time, you will be asked to download the plug-in which will take only a few seconds. In case plug-in can’t be downloaded, a web browser which enables attending the webinar, opens automatically.Registered...

AS Tallinna Sadam kutsub huvilisi osalema ettevõtte 2020. a II kvartali ja 6 kuu majandustulemusi tutvustaval veebiseminaril 14. augustil 2020 kell 11.00 EET. Veebiseminar toimub inglise keeles.Ettevõtte tulemusi tutvustavad ja küsimustele vastavad juhatuse esimees Valdo Kalm ja juhatuse liige/ finantsjuht Marko Raid. Küsimustele vastamine toimub peale esitlust. Kuna veebiseminari aeg on piiratud, soovitame küsimused saata enne veebiseminari algust e-mailile: m.zirel@ts.ee.Veebiseminaril osalemine:Veebiseminaril osalemiseks saab registreeruda siinTeile saadetakse link veebiseminarile ning juhised keskkonna kasutamiseks. Kui osalete veebiseminaril esimest korda, palutakse alla laadida vajalik rakendus. Juhul kui rakenduse allalaadimine ei õnnestu, avaneb automaatselt veebibrauser, mis võimaldab veebiseminari kuulata.Osalejatele saadetakse...

– Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 –– On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in 2020 –– Ended the quarter with $127.2 million in cash, cash equivalents and investments –– Company to host conference call and webcast today at 8:00 AM ET –CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.“We made great strides in the second quarter and this year as a whole has proven to be a time of execution and important...

SUNNYVALE, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), the leading provider of customer engagement solutions, today announced that management will participate in a fireside chat at the Oppenheimer 23rd Annual Technology, Internet & Communications virtual conference on Tuesday, August 11, 2020 at 1:00pm ET and will be available for one-on-one meetings with investors throughout the day on August 11th and 12th.For additional information or to schedule a meeting with eGain management, please contact either your Oppenheimer representative, or MKR Investor Relations, eGain’s investor relations firm, at egan@mkr-group.com.To access a live webcast or replay of the fireside chat, visit the investor relations section of eGain’s website at http://www.egain.com/company/investors/.About eGaineGain customer engagement...

OSLO, NORWAY (7 August 2020) – TGS hereby invites you to participate at a conference call and Q&A session for analysts and investors related to offer to acquire the multi-client data library of PGS, announced 6 August 2020.Time: 7 August 2020 at 15:00 CESTPresenter: Kristian Johansen, CEODial-in details:PIN Code for all countries: 938720Norway: + 47-21-956342Sweden: +46-8-1241-0952Denmark: +45 7876 8490UK: +44-203-7696819USA: +1 646-787-0157Please dial in 5-10 minutes prior to the call to ensure that you will be connected in time.For further information, please contact: Sven Børre LarsenHead of Business Development and M&ATel: +47 909 43 673E-mail: sven.larsen@tgs.com Fredrik AmundsenCFOTel: +47 995 89 882E-mail: fredrik.amundsen@tgs.com About TGS TGS-NOPEC Geophysical Company ASA (TGS) provides multi-client geoscience data...

Die globale Phase-II/III-Studie zu Opaganib soll bis zu 270 Patienten mit schwerem COVID-19 an 40 Prüfzentren aufnehmen.—Die globale Phase-II/III-Studie wurde in Mexiko, Großbritannien und Russland genehmigt und wird auch in Italien, Brasilien und weiteren Ländern geprüft.—Die Aufnahme in eine parallele Phase-II-Studie mit Patienten mit schwerem COVID-19 in den USA ist zu etwa 50 % fortgeschritten und wird voraussichtlich in diesem Monat abgeschlossen.—Mögliche Einreichung weltweiter Anträge für den Notfalleinsatz bereits für das vierte Quartal 2020 geplantTEL-AVIV (Israel) und RALEIGH, NC (USA), Aug. 07, 2020 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (Nasdaq: RDHL) („RedHill“ oder das „Unternehmen“), ein spezialisiertes biopharmazeutisches Unternehmen, hat heute die Genehmigung seines CTA-Antrags (Clinical Trial...

ST. LOUIS, Aug. 07, 2020 (GLOBE NEWSWIRE) — Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today announced it will attend the following investor conferences during fourth quarter of fiscal 2020:Additional details to be available at https://investors.amdocs.com.Supporting ResourcesLearn more about Amdocs Investor RelationsKeep up with Amdocs news by visiting the company’s websiteSubscribe to Amdocs’ RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTubeAbout AmdocsAmdocs’ purpose is to enrich lives and progress society, using creativity and technology to build a better connected world. Amdocs and its 25,000 employees partner with the leading players in the communications and media industry, enabling next-generation experiences in 85 countries. Our cloud-native,...